The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Cell Cycle and Cancer
Open accessAbstract
Cancer is frequently considered to be a disease of the cell cycle. As such, it is not surprising that the deregulation of the cell cycle is one of the most frequent alterations during tumor development. Cell cycle progression is a highlyordered and tightly-regulated process that involves multiple checkpoints that assess extracellular growth signals, cell size, and DNA integrity. Cyclin-dependent kinases (CDKs) and their cyclin partners are positive regulators or accelerators that induce cell cycle progression; whereas, cyclindependent kinase inhibitors (CKIs) that act as brakes to stop cell cycle progression in response to regulatory signals are important negative regulators. Cancer originates from the abnormal expression or activation of positive regulators and functional suppression of negative regulators. Therefore, understanding the molecular mechanisms of the deregulation of cell cycle progression in cancer can provide important insights into how normal cells become tumorigenic, as well as how new cancer treatment strategies can be designed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 3×
“, 1993), has been mapped to chromosome 9p21 (Kamb et al., 1994).”
Backgroundpl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 1×
“One important target of pRB for regulating the early G1 cell cycle progression is the E2F family of transcription factors (Harbour and Dean, 2000).”
BackgroundMatushansky, I., Radparvar, F., & Skoultchi, A. I. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250488697 · Cited by 84
Cited by
Zhang, L.-Y., Bai, M.-Y., Wu, J., Zhu, J.-Y., Wang, H., Zhang, Z., Wang, W., Sun, Y., Zhao, J., Sun, X., et al. (2010) · The Plant Cell · doi:10.1105/tpc.109.070441 · Cited by 487
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
RWRMDA: predicting novel human microRNA–disease associations
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25180a · Cited by 433
Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer
Schumacher, M., Kelkel, M., Dicato, M., & Diederich, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.02.002 · Cited by 138
Giacometti, C., Bellan, E., Ambrosi, A., Dei Tos, A. P., Cassaro, M., & Ludwig, K. (2021) · Placenta · doi:10.1016/j.placenta.2021.02.010 · Cited by 11
Metadata
- Authors
- Park, M.-T., & Lee, S.-J.
- Venue
- BMB Reports
- Published
- 2003-01-31
- Volume
- 36
- Issue
- 1
- Pages
- 60-65
- ISSN
- 1976-6696 (ISSN-L)
- OpenAlex
- W2124173308
- Cited by
- 200
- References
- 5
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Cycle and Cancer. https://app.cochat.ai/papers/10.5483/bmbrep.2003.36.1.060
- The paper
- Park, M.-T., & Lee, S.-J. (2003). Cell Cycle and Cancer. BMB Reports. https://doi.org/10.5483/bmbrep.2003.36.1.060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.